Theodoor J. M. Ruers

Theodoor J. M. Ruers

Auto-generated profile, based on publicly available information

Theodoor J. M. Ruers

Netherlands Cancer Institute

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
TRTheo Ruers
Theo Ruers
FCFrits Van Coevorden
Frits Van Coevorden
CPCornelis J. A. Punt
Cornelis J. A. Punt
JPJean-Pierre E. N. Pierie
Jean-Pierre E. N. Pierie
IBInne Borel-Rinkes
Inne Borel-Rinkes
BNBernard Nordlinger
Bernard Nordlinger
Tumor ablation is often employed for unresectable colorectal liver metastases. However, no survival benefit hasever been demonstrated in prospective randomized studies. Here, we investigate the long-term benefits of such an aggressive approach. In this randomized phase II trial, 119 patients with unresectable colorectal liver metastases (n < 10 and no extrahepatic disease) received systemic treatment alone or systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection. Previously, we reported that the primary end point (30-month overall survival [OS] > 38%) was met. We now report on long-term OS results. All statistical tests were two-sided. The analyses were according to intention to treat. At a median follow up of 9.7 years, 92 of 119 (77.3%) patients had died: 39 of 60 (65.0%) in the combined modality arm and 53 of 59 (89.8%) in the systemic treatment arm. Almost all patients died of progressive disease (35 patients in the combined modality arm, 49 patients in the systemic treatment arm). There was a statistically significant difference in OS in favor of the combined modality arm (hazard ratio [HR] = 0.58, 95% confidence interval [CI] = 0.38 to 0.88, P = .01). Three-, five-, and eight-year OS were 56.9% (95% CI = 43.3% to 68.5%), 43.1% (95% CI = 30.3% to 55.3%), 35.9% (95% CI = 23.8% to 48.2%), respectively, in the combined modality arm and 55.2% (95% CI = 41.6% to 66.9%), 30.3% (95% CI = 19.0% to 42.4%), 8.9% (95% CI = 3.3% to 18.1%), respectively, in the systemic treatment arm. Median OS was 45.6 months (95% CI = 30.3 to 67.8 months) in the combined modality arm vs 40.5 months (95% CI = 27.5 to 47.7 months) in the systemic treatment arm. This phase II trial is the first randomized study demonstrating that aggressive local treatment can prolong OS in patients with unresectable colorectal liver metastases.

19 March 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
TRT. Ruers
T. Ruers
CPC. Punt
C. Punt
FCF. Van Coevorden
F. Van Coevorden
JPJ. P. E. N. Pierie
J. P. E. N. Pierie
IBI. Borel-Rinkes
I. Borel-Rinkes
BNB. Nordlinger
B. Nordlinger
This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. This phase II study, originally started as a phase III design, randomly assigned 119 patients with non-resectable colorectal liver metastases between systemic treatment (n = 59) or systemic treatment plus RFA ( ± resection) (n = 60). Primary objective was a 30-month overall survival (OS) rate >38% for the combined treatment group. The primary end point was met, 30-month OS rate was 61.7% [95% confidence interval (CI) 48.2–73.9] for combined treatment. However, 30-month OS for systemic treatment was 57.6% (95% CI 44.1–70.4), higher than anticipated. Median OS was 45.3 for combined treatment and 40.5 months for systemic treatment (P = 0.22). PFS rate at 3 years for combined treatment was 27.6% compared with 10.6% for systemic treatment only (hazard ratio = 0.63, 95% CI 0.42–0.95, P = 0.025). Median progression-free survival (PFS) was 16.8 months (95% CI 11.7–22.1) and 9.9 months (95% CI 9.3–13.7), respectively. This is the first randomized study on the efficacy of RFA. The study met the primary end point on 30-month OS; however, the results in the control arm were in the same range. RFA plus systemic treatment resulted in significant longer PFS. At present, the ultimate effect of RFA on OS remains uncertain.

25 September 2020 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
STStojan Trajanovski
Stojan Trajanovski
CSCaifeng Shan
Caifeng Shan
PWPim J. C. Weijtmans
Pim J. C. Weijtmans
SKSusan G. Brouwer de Koning
Susan G. Brouwer de Koning
TRTheo J. M. Ruers
Theo J. M. Ruers
Objective: The utilization of hyperspectral imaging (HSI) in real-time tumor segmentation during a surgery have recently received much attention, but it remains a very challenging task. Methods: In this work, we propose semantic segmentation methods and compare them with other relevant deep learning algorithms for tongue tumor segmentation. To the best of our knowledge, this is the first work using deep learning semantic segmentation for tumor detection in HSI data using channel selection and accounting for more spatial tissue context and global comparison between the prediction map and the annotation per sample. Results and Conclusion: On a clinical data set with tongue squamous cell carcinoma, our best method obtains very strong results of average dice coefficient and area under the ROC-curve of 0.891 +/- 0.053 and 0.924 +/- 0.036, respectively on the original spatial image size. The results show that a very good performance can be achieved even with a limited amount of data. We demonstrate that important information regarding tumor decision is encoded in various channels, but some channel selection and filtering is beneficial over the full spectra. Moreover, we use both visual (VIS) and near-infrared (NIR) spectrum, rather than commonly used only VIS spectrum; although VIS spectrum is generally of higher significance, we demonstrate NIR spectrum is crucial for tumor capturing in some cases. Significance: The HSI technology augmented with accurate deep learning algorithms has a huge potential to be a promising alternative to digital pathology or a doctors' supportive tool in real-time surgeries.

19 December 2018 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
LBLisanne De Boer
Lisanne De Boer
TBTorre Bydlon
Torre Bydlon
FDFrederieke van Duijnhoven
Frederieke van Duijnhoven
MPMarie-Jeanne T. F. D. Vranken Peeters
Marie-Jeanne T. F. D. Vranken Peeters
CLClaudette E. Loo
Claudette E. Loo
TRTheo J. M. Ruers
Theo J. M. Ruers
Background: Breast cancer surgeons struggle with differentiating healthy tissue from cancer at the resection margin during surgery. We report on the feasibility of using diffuse reflectance spectroscopy (DRS) for real-time in vivo tissue characterization. Methods: Evaluating feasibility of the technology requires a setting in which measurements, imaging and pathology have the best possible correlation. For this purpose an optical biopsy needle was used that had integrated optical fibers at the tip of the needle. This approach enabled the best possible correlation between optical measurement volume and tissue histology. With this optical biopsy needle we acquired real-time DRS data of normal tissue and tumor tissue in 27 patients that underwent an ultrasound guided breast biopsy procedure. Five additional patients were measured in continuous mode in which we obtained DRS measurements along the entire biopsy needle trajectory. We developed and compared three different support vector machine based classification models to classify the DRS measurements. Results: With DRS malignant tissue could be discriminated from healthy tissue. The classification model that was based on eight selected wavelengths had the highest accuracy and Matthews Correlation Coefficient (MCC) of 0.93 and 0.87, respectively. In three patients that were measured in continuous mode and had malignant tissue in their biopsy specimen, a clear transition was seen in the classified DRS measurements going from healthy tissue to tumor tissue. This transition was not seen in the other two continuously measured patients that had benign tissue in their biopsy specimen. Conclusions: It was concluded that DRS is feasible for integration in a surgical tool that could assist the breast surgeon in detecting positive resection margins during breast surgery. Trail registration NIH US National Library of Medicine–clinicaltrails.gov, NCT01730365. Registered: 10/04/2012 https://clinicaltrials.gov/ct2/show/study/NCT01730365

6 May 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JHJoost Huiskens
Joost Huiskens
TGThomas M van Gulik
Thomas M van Gulik
KLKrijn P van Lienden
Krijn P van Lienden
MEMarc Rw Engelbrecht
Marc Rw Engelbrecht
GMGerrit A Meijer
Gerrit A Meijer
CPCornelis Ja Punt
Cornelis Ja Punt
Colorectal cancer patients with unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and the lack of consensus on criteria for (un)resectability complicates the interpretation of published results. CAIRO5 is a multicentre, randomised, phase 3 clinical study. Colorectal cancer patients with initially unresectable liver-only metastases are eligible, and will not be selected for potential resectability. The (un)resectability status is prospectively assessed by a central panel consisting of at least one radiologist and three liver surgeons, according to predefined criteria. Tumours of included patients will be tested for RAS mutation status. Patients with RAS wild type tumours will be treated with doublet chemotherapy (FOLFOX or FOLFIRI) and randomised between the addition of either bevacizumab or panitumumab, and patients with RAS mutant tumours will be randomised between doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab or triple chemotherapy (FOLFOXIRI) plus bevacizumab. Radiological evaluation to assess conversion to resectability will be performed by the central panel, at an interval of two months. The primary study endpoint is median progression-free survival. Secondary endpoints are the R0/1 resection rate, median overall survival, response rate, toxicity, pathological response of resected lesions, postoperative morbidity, and correlation of baseline and follow-up evaluation with respect to outcomes by the central panel. CAIRO5 is a prospective multicentre trial that investigates the optimal systemic induction therapy for patients with initially unresectable, liver-only colorectal cancer metastases. CAIRO 5 is registered at European Clinical Trials Database (EudraCT) (2013-005435-24). CAIRO 5 is registered at ClinicalTrials.gov: NCT02162563 , June 10, 2014.

7 October 2022 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
WMWitteveen Mark
Witteveen Mark
HJCM SterenborgHJCM Sterenborg
HJCM Sterenborg
TLTon van Leeuwen
Ton van Leeuwen
MAMaurice Aalders
Maurice Aalders
TRTheo J. M. Ruers
Theo J. M. Ruers
APAnouk L. Post
Anouk L. Post
Hyperspectral imaging can be used in medical applications to distinguish tissue types based on differences in their spectral signature.1 – 5 Currently, many researchers use a variety of methods to develop classification algorithms for hyperspectral imaging, such as machine learning, statistical analysis, or fitting algorithms, which identify tissue types based on spectral differences between tissue types. The quality of the data used by the classification algorithm influences the accuracy and robustness of the developed algorithm. Ideally, the spectra used to distinguish tissue types are only influenced by the tissue composition, but unfortunately these spectra are also influenced by other factors, such as surface reflections and sample thickness variations. Removing influences not related to tissue composition is expected to improve the accuracy of the developed algorithm itself, and it would also make the developed algorithm more generalizable, because it does not depend on the amount of surface reflections and sample thickness variations present in the dataset used to develop the algorithm. Thus, reducing these influences is a valuable step in the development of classification algorithms for hyperspectral imaging.